Back to Search
Start Over
Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study
- Source :
- ResearcherID, The American Journal of Clinical Nutrition, The American Journal of Clinical Nutrition, 2007, 86 (6), pp.1670-1679. ⟨10.1093/ajcn/86.5.1670⟩, American Journal of Clinical Nutrition, American Journal of Clinical Nutrition, American Society for Nutrition, 2007, 86 (6), pp.1670-1679. ⟨10.1093/ajcn/86.5.1670⟩
-
Abstract
- Background: Information is lacking on the potential effect of n3 polyunsaturatedfattyacids(PUFAs)ontheadiposetissueofpatients with type 2 diabetes. Objective: We evaluated whether n3 PUFAs have additional effects on adiposity, insulin sensitivity, adipose tissue function (production of adipokines and inflammatory and atherogenic factors), and gene expression in type 2 diabetes. Design: Twenty-seven women with type 2 diabetes without hypertriglyceridemia were randomly allocated in a double-blind parallel design to 2 mo of 3 g/d of either fish oil (1.8 g n3 PUFAs) or placebo (paraffin oil). Results: Although body weight and energy intake measured by use of a food diary were unchanged, total fat mass (P 0.019) and subcutaneous adipocyte diameter (P 0.0018) were lower in the fish oil group than in the placebo group. Insulin sensitivity was not significantlydifferentbetweenthe2groups(measuredbyhomeostasis model assessment in all patients and by euglycemichyperinsulinemic clamp in a subgroup of 5 patients per group). By contrast, atherogenic risk factors, including plasma triacylglycerol (P 0.03), the ratio of triacylglycerol to HDL cholesterol (atherogenic index, P 0.03), and plasma plasminogen activator inhibitor-1 (P 0.01), were lower in the fish oil group than in the placebo group. In addition, a subset of inflammation-related genes wasreducedinsubcutaneousadiposetissueafterthefishoil,butnot the placebo, treatment. Conclusions: A moderate dose of n3 PUFAs for 2 mo reduced adiposity and atherogenic markers without deterioration of insulin sensitivity in subjects with type 2 diabetes. Some adipose tissue inflammation-related genes were also reduced. These beneficial effects could be linked to morphologic and inflammatory changes in adipose tissue. This trial was registered at clinicaltrials.gov as NCT0037. Am J Clin Nutr 2007;86:1670–9.
- Subjects :
- Blood Glucose
medicine.medical_specialty
030309 nutrition & dietetics
[SDV]Life Sciences [q-bio]
medicine.medical_treatment
education
Subcutaneous Fat
Medicine (miscellaneous)
Adipose tissue
Adipokine
030209 endocrinology & metabolism
Type 2 diabetes
Biology
03 medical and health sciences
chemistry.chemical_compound
Fish Oils
0302 clinical medicine
Insulin resistance
Adipokines
Double-Blind Method
Internal medicine
Adipocyte
Diabetes mellitus
Fatty Acids, Omega-3
Plasminogen Activator Inhibitor 1
medicine
Humans
Insulin
Triglycerides
Oligonucleotide Array Sequence Analysis
2. Zero hunger
0303 health sciences
Nutrition and Dietetics
Body Weight
Hypertriglyceridemia
Middle Aged
medicine.disease
3. Good health
Cholesterol
Endocrinology
Diabetes Mellitus, Type 2
Gene Expression Regulation
chemistry
Female
Insulin Resistance
Subjects
Details
- ISSN :
- 00029165 and 19383207
- Database :
- OpenAIRE
- Journal :
- ResearcherID, The American Journal of Clinical Nutrition, The American Journal of Clinical Nutrition, 2007, 86 (6), pp.1670-1679. ⟨10.1093/ajcn/86.5.1670⟩, American Journal of Clinical Nutrition, American Journal of Clinical Nutrition, American Society for Nutrition, 2007, 86 (6), pp.1670-1679. ⟨10.1093/ajcn/86.5.1670⟩
- Accession number :
- edsair.doi.dedup.....6b0b0a37373ffbf910594411cf39a703
- Full Text :
- https://doi.org/10.1093/ajcn/86.5.1670⟩